CA-BOEHRINGER-INGELHEIM
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abu Dhabi Unveils World’s First AI Public Servant at GITEX Global 202514.10.2025 00:23:00 CEST | Press release
Abu Dhabi is unveiling the world’s first AutoGov function with the latest version of TAMM today at GITEX Global 2025. AutoGov automatically manages recurring tasks — from license renewals and utility payments to scheduling routine healthcare appointments — running in the background of daily life so that people have more time to do the things they love and never have to worry about routine services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013919760/en/ His Excellency Ahmed Tamim Hisham Al Kuttab, Chairman of the Department of Government Enablement – Abu Dhabi (DGE) (Photo: AETOSWire) The TAMM AutoGov function launch takes service delivery to the next level, marking a pivotal milestone in Abu Dhabi’s journey to becoming the world’s first AI-native government, representing the next generation of integrated intelligent service delivery. It can automatically manage recurring services, with users having the ability to se
Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market14.10.2025 00:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced the Cessna Citation CJ3 Gen2 has achieved Federal Aviation Administration (FAA) type certification, bringing the most comprehensive Citation Gen2 investment to market. Based on customer feedback, enhancements throughout the aircraft include Garmin autothrottle technology, an additional 4.5 inches of legroom for pilots and a fully customizable cabin environment. After completing 445 flight test hours, the light jet is expected to enter into service this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013311527/en/ Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market (Photo Credit: Textron Aviation). “FAA certification of the CJ3 Gen2 is an example of Textron Aviation’s leadership in certifying aircraft,” said Chris Hearne, senior vice president, Engineering & Programs. “This aircraft de
Cessna Citation M2 Gen2 with Garmin Autothrottles Achieves FAA Certification, Bringing Greater Control and Precision to Pilots14.10.2025 00:00:00 CEST | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently received certification from the Federal Aviation Administration (FAA), bringing greater control and precision to pilots. The integration of Garmin’s Autothrottle system in the M2 Gen2 further supports the most delivered light-entry jet’s capabilities by optimizing engine power, simplifying flight management and increasing overall operating efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013861341/en/ Cessna Citation M2 Gen2 with Garmin Autothrottles achieves FAA certification, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. The flight test program for the Citation M2 Gen2 with autothrottles completed nearly 300 flight test hours and numerous certification tests, adhering to stringent certification stan
HCLTech Delivers Robust Performance in Q2FY26 with Revenue Growth of 4.6%13.10.2025 20:08:00 CEST | Press release
Deal wins at $2.6B; Advanced AI revenue crosses $100m HCLTech, a leading global technology company, reported 4.6% YOY revenue growth in constant currency (CC) for the quarter ended September 30, 2025. USD revenue was at $3.6 billion, up 5.8% YoY. The company revised its Services Revenue growth (CC) guidance to 4%-5%, while retaining the overall revenue and margin guidance for FY26. “We had a standout quarter on every front — marked by strong execution, growing demand for our AI-powered solutions and Advanced AI revenue exceeding $100 million this quarter. Our AI strategy is no longer just a vision; it is now a measurable driver of growth, differentiation and innovation. We are transitioning into an AI monetization phase. For the first time, our new bookings surpassed $2.5 billion, without reliance on any mega deal,” said C Vijayakumar, CEO & Managing Director, HCLTech. HCLTech’s Services revenue grew by 5.5% YoY (CC). Digital revenue was up 15% YoY (CC) and now accounts for 42% of Serv
Cessna Citation Ascend Makes World Debut at NBAA-BACE in Las Vegas13.10.2025 19:00:00 CEST | Press release
The Cessna Citation Ascend landed today at Henderson Executive Airport in Las Vegas, marking its world debut at the 2025 National Business Aviation Association Business Aviation Convention & Exhibition (NBAA-BACE). The aircraft, which flew to the show using sustainable aviation fuel, will be on display Tuesday, October 14 and Wednesday, 15 alongside other industry-leading Cessna Citation business jets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013102318/en/ Cessna Citation Ascend makes world debut at NBAA-BACE in Las Vegas (Photo Credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “We asked our customers what they wanted in this iconic aircraft, and our teams worked to bring their vision for the Citation Ascend to life,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “With the aircraft making its debut at NBAA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom